Rimonabant (ACOMPLIA®): First CB1 receptor antagonist of the endocannabinoid system;Le médicament du mois. Rimonabant (ACOMPLIA®): Premier antagoniste des récepteurs CB1 du système endocannabinoïde

Revue Medicale de Liege

Volumn 63, Issue 1, 2008, Pages 50-55

  Scheen, A J ^a,b   Van Gaal, L F ^c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Hôpital Universitaire d'Anvers

Author keywords

Cardiovascular risk; Dyslipidaemia; Endocannabinoid system; Obesity; Rimonabant; Type 2 diabetes

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; RIMONABANT; SULFANILAMIDE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANXIETY; ARTICLE; ATHEROGENIC DIET; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DIET; DRUG EFFICACY; DYSLIPIDEMIA; EXERCISE; HUMAN; INSULIN RESISTANCE; MOOD DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID;

EID: 41149166720     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pagotto U, Marsicano G, Cota D, et al. - The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev, 2006, 27, 73-100.
2. Pacher P, Batkai S, Kunos G. - The endocannabioid system as an emerging target of pharmacotherapy. Pharmacol Rev, 2006, 58, 389-462.
3. Matias I, Gonthier MP, Orlando P, et al. - Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab, 2006, 91, 3171-3180.
4. Cote M, Matias I, Lemieux I, et al. - Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obesity, 2007, 31, 692-699.
5. Scheen AJ. - Current management strategies for coexisting diabetes mellitus and obesity. Drugs, 2003, 63, 1165-1184.
6. Van Gaal LF, Mertens IL, De Block CE. - Mechanisms linking obesity with cardiovascular disease. Nature, 2006, 444, 875-880.
7. Curioni C, Andre C. - Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews, 2006, 4, 4.
8. Scheen AJ, Van Gaal LF. - Effets cardio-métaboliques du rimonabant chez le sujet obèse ou en surpoids avec dyslipidémie ou diabète de type 2. Rev Med Liège, 2007, 62, 81-85.
9. Henness S, Robinson DM, Lyseng-Williamson KA. - Rimonabant. Drugs, 2006, 66, 2109-2119.
10. Xie S, Furjanic MA, Ferrara JJ, et al. - The endocannabinoid system and rimonabant : a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use. J Clin Pharm Ther, 2007, 32, 209-231.
11. Cahill K, Ussher M. - Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev, 2007 (3): CD005353.
12. Van Gaal LF, Rissanen AM, Scheen AJ, et al. - Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients : 1-year experience from the RIO-Europe study. Lancet, 2005, 365, 1389-1397.
13. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. - Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America : a randomized controlled trial. JAMA, 2006, 295, 761-775.
14. Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group. - Effects on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med, 2005, 353, 2121-2134.
15. Scheen AJ, Finer N, Hollander P, et al for the RIO-Diabetes Study Group. - Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet, 2006, 368, 1660-1672.
16. Van Gaal LF, Pi-Sunyer X, Després JP, et al. - Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the RIO program. Diabetes Care, 2008 (in press).
17. Lafontan M, Piazza PV, Girard J. - Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab, 2007, 33, 85-95.
18. Scheen AJ. - Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res Clin Endocrinol Metab, 2007, 21, 535-553.
19. Scheen AJ, Van Gaal LF. - Le diabète de type 2 au coeur du syndrome métabolique : plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.
20. Christensen R, Kristensen PK, Bartels EM, et al. - Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet, 2007, 370, 1706-1713.
21. Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/07/ briefmg/2007-4306b1-00-index.htm.
22. Acomplia European Public Assessment Report. - Summary of Product Characteristics, www.emea.europa. eu/humandocs/PDFs/EPAR/acomplia/H-666-PI-en. pdf. (accessed 21 November 2007).
23. Padwal RS, Majumdar SR. - Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet, 2007, 369, 71-77.
24. Rucker D, Padwal R, Li SK, et al. - Long term pharmacotherapy for obesity and overweight : updated meta-analysis. BMJ, 2007, 335, 1194-1199.